Shares of the small-cap immunotherapy company Agenus (NASDAQ: AGEN) were exceedingly volatile over the whole of 2021. Turning to the specifics, Agenus' stock first gained a healthy 55% during the first month of the year, before giving back all of these gains plus another 10%, according to data provided by market Intelligence - opens in new tab" data-uw-rm-brl="false" data-uw-rm-ext-link="" data-uw-styling-context="true" href="http://marketintelligence.spglobal.com/" target="_blank"> S&P Global Market Intelligence .
In May 2021, Agenus' stock went on a second major rally, with the drugmaker's shares more than doubling in value from their intra-year lows. Thanks to a key regulatory setback in the fourth quarter, however, Agenus' stock crashed toward the end of the year, ending down a whopping 51% from its 52-week high.
For further details see:
Why Agenus Stock Took Investors for a Wild Ride in 2021